Aisling Capital Management as of March 31, 2021
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 15 positions in its portfolio as reported in the March 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 67.3 | $374M | 6.1M | 61.60 | |
| Harmony Biosciences Hldgs In (HRMY) | 5.0 | $28M | 843k | 33.04 | |
| Nuvation Bio Com Cl A (NUVB) | 4.8 | $27M | 2.5M | 10.45 | |
| Syndax Pharmaceuticals (SNDX) | 4.1 | $23M | 1.0M | 22.36 | |
| Spruce Biosciences (SPRB) | 3.6 | $20M | 1.2M | 16.60 | |
| Aclaris Therapeutics (ACRS) | 2.9 | $16M | 635k | 25.20 | |
| Aeglea Biotherapeutics | 2.4 | $13M | 1.7M | 7.92 | |
| Avrobio Ord (AVRO) | 2.3 | $13M | 1.0M | 12.69 | |
| Verona Pharma Sponsored Ads (VRNA) | 2.0 | $11M | 1.3M | 8.36 | |
| Poseida Therapeutics I (PSTX) | 1.8 | $10M | 1.0M | 9.55 | |
| Marker Therapeutics Ord | 1.3 | $7.0M | 3.1M | 2.24 | |
| Atreca Cl A Com (BCEL) | 1.1 | $5.9M | 388k | 15.33 | |
| Obseva Sa | 0.8 | $4.5M | 1.4M | 3.25 | |
| Zosano Pharma Corporation Com New | 0.6 | $3.4M | 2.7M | 1.24 | |
| Nabriva Therapeutics SHS | 0.1 | $317k | 191k | 1.66 |
